The role of glial cells in Parkinsonʼs disease
Abstract
Parkinson's disease is a common neurodegenerative disorder characterized by the progressive loss of the dopaminergic neurons in the substantia nigra pars compacta. The loss of these neurons is associated with a glial response composed mainly of activated microglial cells and, to a lesser extent, of reactive astrocytes. This glial response may be the source of trophic factors and can protect against reactive oxygen species and glutamate. Aside from these beneficial effects, the glial response can mediate a variety of deleterious events related to the production of reactive species, and pro-inflammatory prostaglandin and cytokines. This article reviews the potential protective and deleterious effects of glial cells in the substantia nigra pars compacta of Parkinson's disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GLP-1 therapy may be beneficial for the treatment of chronic inflammatory diseases including nonalcoholic steatohepatitis, atherosclerosis, neurodegenerative disorders, diabetic nephropathy, asthma, and psoriasis.
“Thus, GLP-1 therapy may be beneficial for the treatment of chronic inflammatory diseases including nonalcoholic steatohepatitis, atherosclerosis, neurodegenerative disorders, diabetic nephropathy, asthma, and psoriasis [14, 26–32].”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [27]
Cites
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · see citing works
Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90229-w · Cited by 2,045 · see citing works
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · see citing works
Self-citationFunctional recovery in parkinsonian monkeys treated with GDNF
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., et al. (1996) · Nature · doi:10.1038/380252a0 · Cited by 955 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · see citing works
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 503 · see citing works
“Microglial activation plays a critical role in the pathogenesis of the 1-methyl-4-phenyl1,2,3,6-tetrahydropyidine- (MPTP-) induced Parkinson’s disease model and human Parkinson’s disease [27].”
BackgroundNeuroprotective effects of hydrogen sulfide on Parkinson’s disease rat models
Hu, L., Lu, M., Tiong, C. X., Dawe, G. S., Hu, G., & Bian, J. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2009.00543.x · Cited by 365 · see citing works
Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., & Pitossi, F. J. (2008) · Brain · doi:10.1093/brain/awn101 · Cited by 335 · see citing works
Hunter, R. L., Dragicevic, N., Seifert, K., Choi, D. Y., Liu, M., Kim, H., Cass, W. A., Sullivan, P. G., & Bing, G. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04327.x · Cited by 322 · see citing works
Self-citationBrodacki, B., Staszewski, J., Toczyłowska, B., Kozłowska, E., Drela, N., Chalimoniuk, M., & Stępien, A. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.040 · Cited by 316 · see citing works
An inflammatory review of Parkinson's disease
Orr, C. F., Rowe, D. B., & Halliday, G. M. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00127-2 · Cited by 309 · see citing works
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263 · see citing works
Ferrari, C. C., Pott Godoy, M. C., Tarelli, R., Chertoff, M., Depino, A. M., & Pitossi, F. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.013 · Cited by 235 · see citing works
Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles
Kurakhmaeva, K. B., Djindjikhashvili, I. A., Petrov, V. E., Balabanyan, V. U., Voronina, T. A., Trofimov, S. S., Kreuter, J., Gelperina, S., Begley, D., & Alyautdin, R. N. (2009) · Journal of Drug Targeting · doi:10.1080/10611860903112842 · Cited by 221 · see citing works
Moon, M., Kim, H. G., Hwang, L., Seo, J.-H., Kim, S., Hwang, S., Kim, S., Lee, D., Chung, H., Oh, M. S., et al. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9037-x · Cited by 203 · see citing works
Zhang, S., Wang, X.-J., Tian, L.-P., Pan, J., Lu, G.-Q., Zhang, Y.-J., Ding, J.-Q., & Chen, S.-D. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-154 · Cited by 154 · see citing works
Khwaja, M., McCormack, A., McIntosh, J. M., Di Monte, D. A., & Quik, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04177.x · Cited by 54 · see citing works
- Authors
- Vila, M., Jackson-Lewis, V., Guégan, C., Chu Wu, D., Teismann, P., Choi, D.-K., Tieu, K., & Przedborski, S.
- Affiliations
- Columbia University (US)
- Corresponding author
- Przedborski, Serge
- Venue
- Current Opinion in Neurology
- Published
- 2001-08
- Volume
- 14
- Issue
- 4
- Pages
- 483-489
- ISSN
- 1350-7540 (ISSN-L)
- OpenAlex
- W2078056296
- Cited by
- 326
- References
- 4
- Citations by year
- 2025: 6 · 2024: 5 · 2023: 12 · 2022: 13 · 2021: 3 · 2020: 6 · 2019: 3 · 2018: 2 · 2017: 7 · 2016: 17 · 2015: 10 · 2014: 13 · 2013: 14 · 2012: 12
- FWCI
- 3.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29ns037345-05)
- National Institute of Neurological Disorders and Stroke (P50-NS38370, R01 NS 38586, R29 NS37345, R01NS038586, P50NS038370)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, glial cells, microglial activation, reactive astrocytes, substantia nigra pars compacta, dopaminergic neuron loss, neuroinflammation, reactive oxygen species, glutamate excitotoxicity, prostaglandins, cytokines, neuroprotection
- MeSH terms
- Astrocytes, Dopamine, Humans, Neurons, Parkinson Disease, Substantia Nigra, Cytokines, Microglia, Chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
